Automated delivery of high-viability therapeutic cell populations following revival from cryopreservation

该项目旨在开发一种商业演示仪器-ReVive受控解冻设备（ReVive-CT），用于细胞治疗领域的客户，这些客户将冷冻产品运送给患者，并需要确保治疗时细胞的最高可行性和再现性。结合核心生物学和工程技术，以便将冷冻保存的治疗性细胞的使用“药物化”-从洁净室到诊所的过渡将被简化，以优化（1）易于交付给患者，（2）高活力和细胞剂量（因此具有高功效），以及（3）交付的高质量产品的一致性和再现性。此外，设想该系统将具有额外的应用-例如在早期生物处理期间-其中来自库存储备的细胞的受控解冻是重要的处理考虑因素。

The project aims to develop a commercial demonstrator instrument - the ReVive Controlled Thaw device (ReVive-CT) to customers within the cell therapy sector who ship frozen product to the patient and need to ensure the highest possible viability and reproducibility of cells at the point of treatment. Combining core biological and engineering skills in order to 'pharmaceuticalise' use of cryopreserved therapeutic cells - the transition from cleanroom to clinic will be streamlined to optimise (1) ease of delivery to the patient, (2) high-viability and cell dosage (and therefore high efficacy), and (3) consistency and reproducibility of high-quality product delivered. Furthermore, it is envisaged that the system will have additional applications - eg during early-stage bioprocessing - where controlled thawing of cells from banked stocks is an important processing consideration.